ImageneBio Inc
IMAAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Wedbush | maintain | Underperform | May 11, 2026 |
| Wedbush | maintain | Neutral | Jul 25, 2025 |
| HC Wainwright & Co. | maintain | Buy | Nov 11, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 12, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 29, 2024 |
| Wedbush | downgrade | Outperform →Neutral | May 29, 2024 |
| Wedbush | maintain | Outperform | May 14, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 19, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 12, 2024 |
| Wedbush | maintain | Outperform | Jan 19, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jan 19, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 9, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 10, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 7, 2023 |
| HC Wainwright & Co. | maintain | Buy | May 24, 2023 |
| Credit Suisse | maintain | Outperform | May 16, 2023 |
| HC Wainwright & Co. | maintain | Buy | Mar 17, 2023 |
| Credit Suisse | maintain | Outperform | Mar 15, 2023 |
| Credit Suisse | maintain | Outperform | Nov 29, 2022 |
| HC Wainwright & Co. | maintain | Buy | Nov 29, 2022 |
| Credit Suisse | maintain | Outperform | Nov 8, 2022 |
| Credit Suisse | maintain | Outperform | May 13, 2022 |
| HC Wainwright & Co. | maintain | Buy | Apr 13, 2022 |
| HC Wainwright & Co. | maintain | Buy | Dec 23, 2021 |
| Credit Suisse | maintain | Outperform | Aug 13, 2021 |
Earnings History
Next report: Nov 11, 2026 · EPS est. $-0.83| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 5, 2026 | $-0.63 | $-0.98 | — | — |
| May 7, 2026 | $-0.95 | $-0.70 | — | — |
| Mar 5, 2026 | $-0.62 | $-1.45 | — | — |
| Nov 12, 2025 | $-2.91 | $-1.47 | — | — |
| Jul 24, 2025 | $-0.06 | $-0.14 | -$500.0K | — |
| May 8, 2025 | $-0.18 | $-0.21 | $800.0K | — |
| Mar 6, 2025 | $-0.18 | $-0.23 | — | $875.0K |
| Nov 7, 2024 | $-0.21 | $-0.27 | — | — |
News
ImageneBio (NASDAQ: IMA - Get Free Report) and Agenus (NASDAQ: AGEN - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability and analyst recommendations. Insider and Institutional Ownership 75.0% of ImageneBio shares are
SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that on September 30, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of 90,775 restricted stock units (“RSUs”) and 32,725 non-qualified stock options (“NSOs”) to three newly hired non-executive employees. The foregoing inducement awards were granted as inducements material to the new empl…
SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that chief executive officer Kristin Yarema, Ph.D., will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York on Sept. 14, 2026, and management will participate in one-on-one meetings.
SAN DIEGO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that on August 14, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of 79,000 restricted stock units (“RSUs”) and 56,525 non-qualified stock options (“NSOs”) to three newly hired non-executive employees. Additionally, the Compensation Committee granted inducement awards consisting of 65,000…